Who Paid My Doc
Bruce Akright
Gynecology Schertz, TX Medical Doctor
NPI 1679515373 CMS profile 30905
5000 Schertz Pkwy, Suite 100, Schertz, TX 78154
General payments
$3,192
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$32,891
Through program year 2023, Bruce Akright of Schertz, TX is reported in the CMS Open Payments database as having received $3,192 across 139 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $32,891 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 81st percentile of Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $271 | 15 | |
| 2022 | General | $651 | 33 | |
| 2021 | General | $614 | 30 | |
| 2020 | General | $247 | 14 | |
| 2019 | General | $1,408 | 47 |
Beside peers
- Bruce Akright
- Gynecology median
- Middle half of Gynecology
- National median
In program year 2025, general payments to Bruce Akright were reported at $0. Among 1,279 Gynecology profiles paid that year, the median was $162 and the middle half received between $56 and $501.
Show as a table
| Year | Bruce Akright | Gynecology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,408 | $199 | $66–$472 | $163 |
| 2020 | $247 | $114 | $42–$287 | $114 |
| 2021 | $614 | $141 | $42–$430 | $132 |
| 2022 | $651 | $173 | $52–$532 | $149 |
| 2023 | $271 | $170 | $57–$501 | $160 |
| 2024 | $0 | $157 | $50–$424 | $164 |
| 2025 | $0 | $162 | $56–$501 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
18
Drug cost
$970
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Estradiol | Generic | 18 | $970 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Records
139 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Gynecology in Texas
Related records
Gynecology in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Gynecology
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.